Suven concall on Nov 25th @ 12:00 noon IST
http://corporates.bseindia.com/xml-data/corpfiling/AttachLive/B901E77E_71AF_44F4_BE5C_89DECBC88977_104427.pdf
Looks like Eli- Lilly also out http://www.bloomberg.com/news/articles/2016-11-23/lilly-s-alzheimer-s-disease-drug-fails-in-final-stage-trial
4 Likes
This also points out to the fact that the molecule can fail even in phase 3 or phase 4 trials and those will be real costs.
Quite a few trials going on
http://www.brightfocus.org/alzheimers/article/clinical-trials-alzheimers-disease-whats-new
1 Like
This shouldnāt directly impact SUVN-201 which is tries to improve brains Cognition by trying to alter serotonin activity. This is in fact an indirect positive as if the research passes - monetization benefits would be much higher. The results to closely watch for are of two competing molecules under development to phase III trials: RVT 101 (GSK, Axovant) and Lu AE58054 (Lundbeck,Otsuka). Both these molecules are ahead of SUVN-502, which is still undergoing phase II tirals. 5-HT6 molecules hit a brain receptor called the serotonin receptor 5HT6.
Lundbeck already failed in phase III.
But the business model of Suven looks different. As per annual report they will sell their molecule for a sum and commision once it becomes sellable in phase 3. They can not afford phase 3 expenditures.
1 Like
Suven to Present at 9th CLINICAL TRIALS ON ALZHEIMERāS DISEASE (CTAD) Conference held during December 8-10, 2016 at San Diego
http://www.suven.com/PressRelease08Dec2016.pdf
1 Like
The complete program for the CTAD conference
Suven is doing poster presentations on Sat (Refer to page 38 from the below link which has the detailed program)
http://www.ctad-alzheimer.com/sites/ctad.prod/files/files/PROGRAMfinal_CTAD2016_1dec.pdf
Promising early-stage results for Biogenās aducanumab treatment
https://www.bostonglobe.com/business/2016/12/09/looks-like-biogen-may-right-track-with-its-alzheimer-drug/UKUYdOZb7qpMpAUiZLljXK/story.html
1 Like
Suven is presenting at Biotech Showcase 2017 on 11th January and attending 35th Annual J.P. Morgan Healthcare Conference at San Francisco
http://corporates.bseindia.com/xml-data/corpfiling/AttachLive/A9A869C9_7BBB_486E_8DB7_5785849F479B_111201.pdf
Suven hires NJ based PR firm to publicize SUVN-502 clinical drug trial in New Jersey and New York
2 Likes
Suven concall on Thursday, Feb 2 at 2.30 p.m. IST
http://corporates.bseindia.com/xml-data/corpfiling/AttachLive/EE57BDFC_3B89_4464_9905_743AD93A8F9F_155518.pdf
on 16th may,
CMP 188.25
it has fallen 4.61% in last 10 days.
As per previous discussion, and my basic understanding, quality of the business is still intact.
over the years the earnings have increased.
P/E 19.84.
Which I am not sure, is suitable for pharma sector or not, as I have very little knowledge in this sector,
Also as per data from screener, 3 year ROE is 29% approx.
which is a good indicator of earnings.
So, as per my basic analysis, Suven looks good.
Seniors please provide your inputs in this current scenario on Suven.
Disc: Not invested, watching closely.
Updates: 25.05.17 : Suven begins Phase I clinical trials for its NCE SUVN-911:
2 Likes
Hello everyone,
Was anyone able to attend the Q1 con call today? If so, can you please share notes from the discussion. Thank you very much!
Co guided for 15% type of growth in both sales and profits.Some delay in suvn502 data will unblinded only by Dec 2018 and post that it can take at least 6 months to know success or failure.Seems to be dull phase for next 2 years
Patents is no new for this wonderful company